A Phase 1 interventional study of lorlatinib and lorlatinib in Advanced Cancers, sponsored by Pfizer. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-21.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 1 study in advanced cancer patients with varied hepatic functions to evaluate the potential effect of hepatic impairment on pharmacokinetics and safety of lorlatinib and provide dose recommendation for patients with hepatic impairment if possible.
This will be a Phase 1, open label, multi center, multiple dose, non randomized, Phase 1 clinical trial of lorlatinib in advanced cancer patients with varying degrees of hepatic impairment and necessary age , weight , and gender matched prospect normal hepatic function patients. This study is intended to evaluate the potential effect of hepatic impairments on the PK and safety of lorlatinib after daily administration of lorlatinib and to provide dosing recommendation for patients with varied degree of hepatic impairment if possible.
Patients in the study will be assigned to different groups (A1, normal liver function, control for group B; A2, normal liver function, control for group C; B, mild hepatic impairment; C, moderate hepatic impairment; D, severe hepatic impairment) according to their liver function. The enrollment of approximately 76 advanced cancer patients is anticipated in this study in order to have 8 PK-evaluable patients in each of Groups A1, A2, B and C, and 6 PK-evaluable patients in Group D for final statistical analysis. Evaluable patients are those who complete the planned PK sample collection on Cycle 2 Day 1 and have no lorlatinib dose modification until completion of Cycle 2 Day 1 PK evaluation. Patients who are not evaluable for PK will be replaced. Each patient will be treated with repeated oral once daily doses of lorlatinib in 21-day cycles until disease progression, patient refusal, or unacceptable toxicity occurs. The dose schedule may be modified as necessary for individual patients according to tolerability.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 1 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
continued daily administration of lorlatinib in patients with normal hepatic function
Drug: lorlatinib
continued daily administration of lorlatinib in patients with normal hepatic function
Drug: lorlatinib
continued daily administration of lorlatinib in patients with mild hepatic impairment
Drug: lorlatinib
continued daily administration of lorlatinib in patients with moderate hepatic impairment
Drug: lorlatinib
continued daily administration of lorlatinib in patients with severe hepatic impairment
Drug: lorlatinib
continued daily administration of 100 mg lorlatinib
continued daily administration of lorlatinib at the dose level same as Group C for the first 22 days and 100 mg QD afterwards
continued daily administration of 100 mg QD lorlatinib
continued daily administration of lorlatinib at 50 mg QD initially and may be adjusted based on PK and safety results from the initial several patients
continued daily administration of lorlatinib at the dose level determined based on preliminary PK and safety results from first several patients in Group C
Area Under Plasma Lorlatinib Concentration-Time Curve From Time 0 to Dosing Interval of 24 Hours (AUC24) at Steady State On Cycle 2 Day 1
AUC24 was defined as area under the plasma concentration time profile during 1 dosing interval (24 hours).
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Observed Maximal Plasma Concentration (Cmax) at Steady State on Cycle 2 Day 1
Cmax was defined as maximum plasma concentration and was observed directly from data.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Number Of Patients Experienced Treatment Emergent Adverse Event Assessed by Investigator
An Adverse event (AE) was any untoward medical occurrence in a participant. A serious AE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or that was considered to be an important medical event. AEs were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. The grades were defined as follows: Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE. The focus of AE summaries was on treatment-emergent AE (TEAE). An AE was considered TEAE if the event occurred during the on-treatment period.
Time frame: From Screening (within 28 days prior to Cycle 1 Day 1) through and including at least 28 days after after the last lorlatinib dose. The duration is approximately 42 days.
Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a best overall confirmed response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 relative to the response-evaluable population.
Time frame: Baseline up to approximately 1 year
Duration of Response (DR)
DR was measured from the date that an objective tumor response (CR or PR) was first documented (whichever occurred first) to date of objective tumor progression or death due to any cause, whichever occurred first.
Time frame: Baseline up to approximately 1 year
Lorlatinib Area Under Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) After Single Dose on Cycle 1 Day 1
AUClast was defined as area under the plasma concentration time profile from time 0 to the time of the last quantifiable concentration (Clast)
Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
The Time of The Last Quantifiable Concentration (Tlast) of Lorlatinib After Single Dose on Cycle 1 Day 1
Tlast was defined as the time of the last quantifiable concentration.
Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
The Time to Cmax (Tmax) of Lorlatinib After Single Dose on Cycle 1 Day 1
Tmax was defined as time for Cmax.
Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Observed Minimal Plasma Concentration (Cmin) at Steady State On Cycle 2 Day 1
Cmin was defined as minimum plasma concentration and was observed directly from data.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Plasma Lorlatinib AUClast at Steady State On Cycle 2 Day 1
AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Plasma Lorlatinib Tlast at Steady State On Cycle 2 Day 1
Tlast was defined as the time of the last quantifiable concentration.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Apparent Clearance (CL/F) at Steady State On Cycle 2 Day 1
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as Dose/AUC24 at steady-state.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Plasma Lorlatinib Metabolite AUC24 at Steady State
AUC24 was defined as area under the plasma concentration time profile during one dosing interval (24 hours).
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Plasma Lorlatinib Metabolite AUClast After Single Dose
AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.
Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Plasma Lorlatinib Metabolite AUClast at Steady State
AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Plasma Lorlatinib Metabolite Cmax After Single Dose
Cmax was defined as maximum plasma concentration and was observed directly from data.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Plasma Lorlatinib Metabolite Cmax at Steady State
Cmax was defined as maximum plasma concentration and was observed directly from data.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Plasma Lorlatinib Metabolite Tlast After Single Dose
Tlast was defined as the time of the last quantifiable concentration.
Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Plasma Lorlatinib Metabolite Tlast at Steady State
Tlast was defined as the time of the last quantifiable concentration.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Metabolite Ratio of Lorlatinib Metabolite for AUC24 (MRAUC24) at Steady State on Cycle 2 Day 1
MRAUC24 was defined as metabolite ratio of lorlatinib metabolite for AUC24.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 2 Day 1
MRAUClast was defined as metabolite ratio of lorlatinib metabolite for AUClast.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Metabolite Ratio of Lorlatinib Metabolite for Cmax (MRCmax) at Steady State on Cycle 2 Day 1
MRCmax was defined as metabolite ratio of lorlatinib metabolite for AUClast.
Time frame: Cycle 2 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 1 Day 1
MRAUClast was defined as metabolite ratio of lorlatinib metabolite for AUClast.
Time frame: Cycle 1 day 1 at times 0 (predose), 0.5, 1, 2, 4, 6, 10, and 24 hours post lorlatinib dose.
| Milestone | Group A1 Normal Hepatic Function | Group A2 Normal Hepatic Function | Group B Mild Hepatic Impairment | Group C Moderate Hepatic Impairment | Group D Severe Hepatic Impairment |
|---|---|---|---|---|---|
| Started | 0 | 0 | 1 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 1 | 0 | 0 |
AUC24 was defined as area under the plasma concentration time profile during 1 dosing interval (24 hours).
| nanogram*hour per milliliter (ng*hr/mL) | Group B Mild Hepatic Impairment |
|---|---|
| Area Under Plasma Lorlatinib Concentration-Time Curve From Time 0 to Dosing Interval of 24 Hours (AUC24) at Steady State On Cycle 2 Day 1 | NA ± NA |
Cmax was defined as maximum plasma concentration and was observed directly from data.
| nanogram per milliliter (ng/mL) | Group B Mild Hepatic Impairment |
|---|---|
| Observed Maximal Plasma Concentration (Cmax) at Steady State on Cycle 2 Day 1 | NA ± NA |
An Adverse event (AE) was any untoward medical occurrence in a participant. A serious AE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect or that was considered to be an important medical event. AEs were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. The grades were defined as follows: Grade 0: no change from normal or reference range; Grade 1: mild AE; Grade 2: moderate AE; Grade 3: severe AE; Grade 4: life-threatening consequences, urgent intervention indicated; Grade 5: death related to AE. The focus of AE summaries was on treatment-emergent AE (TEAE). An AE was considered TEAE if the event occurred during the on-treatment period.
| Participants | Group B Mild Hepatic Impairment |
|---|---|
| All-causality TEAEs | NA |
| Treatment-related TEAEs | NA |
| All-causality serious AEs | NA |
| Treatment-related serious AEs | NA |
| All-causalities AEs ≥Grade 3 | NA |
| Treatment-related AEs ≥Grade 3 | NA |
| All-causalities Grade 1 AEs | NA |
| Treatment-related Grade 1 AEs | NA |
| All-causalities Grade 2 AEs | NA |
| Treatment-related Grade 2 AEs | NA |
ORR was defined as the percentage of participants with a best overall confirmed response of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 relative to the response-evaluable population.
| Percentage of participants | Group B Mild Hepatic Impairment |
|---|---|
| Objective Response Rate (ORR) | 0 (0 to 97.5) |
DR was measured from the date that an objective tumor response (CR or PR) was first documented (whichever occurred first) to date of objective tumor progression or death due to any cause, whichever occurred first.
| Months | Group B Mild Hepatic Impairment |
|---|---|
| Duration of Response (DR) | NA (NA to NA) |
AUClast was defined as area under the plasma concentration time profile from time 0 to the time of the last quantifiable concentration (Clast)
| ng*hr/mL | Group B Mild Hepatic Impairment |
|---|---|
| Lorlatinib Area Under Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) After Single Dose on Cycle 1 Day 1 | NA ± NA |
Tlast was defined as the time of the last quantifiable concentration.
| hour | Group B Mild Hepatic Impairment |
|---|---|
| The Time of The Last Quantifiable Concentration (Tlast) of Lorlatinib After Single Dose on Cycle 1 Day 1 | NA (NA to NA) |
Tmax was defined as time for Cmax.
| hour | Group B Mild Hepatic Impairment |
|---|---|
| The Time to Cmax (Tmax) of Lorlatinib After Single Dose on Cycle 1 Day 1 | NA (NA to NA) |
Cmin was defined as minimum plasma concentration and was observed directly from data.
| ng/mL | Group B Mild Hepatic Impairment |
|---|---|
| Observed Minimal Plasma Concentration (Cmin) at Steady State On Cycle 2 Day 1 | NA ± NA |
AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.
| ng*hr/mL | Group B Mild Hepatic Impairment |
|---|---|
| Plasma Lorlatinib AUClast at Steady State On Cycle 2 Day 1 | NA ± NA |
Tlast was defined as the time of the last quantifiable concentration.
| hour | Group B Mild Hepatic Impairment |
|---|---|
| Plasma Lorlatinib Tlast at Steady State On Cycle 2 Day 1 | NA (NA to NA) |
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as Dose/AUC24 at steady-state.
| Liter per hour (L/hr) | Group B Mild Hepatic Impairment |
|---|---|
| Apparent Clearance (CL/F) at Steady State On Cycle 2 Day 1 | NA ± NA |
AUC24 was defined as area under the plasma concentration time profile during one dosing interval (24 hours).
| ng*hr/mL | Group B Mild Hepatic Impairment |
|---|---|
| Plasma Lorlatinib Metabolite AUC24 at Steady State | NA ± NA |
AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.
| ng*hr/mL | Group B Mild Hepatic Impairment |
|---|---|
| Plasma Lorlatinib Metabolite AUClast After Single Dose | NA ± NA |
AUClast was defined as area under the plasma concentration time profile from time 0 to the time of Clast.
| ng*hr/mL | Group B Mild Hepatic Impairment |
|---|---|
| Plasma Lorlatinib Metabolite AUClast at Steady State | NA ± NA |
Cmax was defined as maximum plasma concentration and was observed directly from data.
| ng/mL | Group B Mild Hepatic Impairment |
|---|---|
| Plasma Lorlatinib Metabolite Cmax After Single Dose | NA ± NA |
Cmax was defined as maximum plasma concentration and was observed directly from data.
| ng/mL | Group B Mild Hepatic Impairment |
|---|---|
| Plasma Lorlatinib Metabolite Cmax at Steady State | NA ± NA |
Tlast was defined as the time of the last quantifiable concentration.
| hour | Group B Mild Hepatic Impairment |
|---|---|
| Plasma Lorlatinib Metabolite Tlast After Single Dose | NA (NA to NA) |
Tlast was defined as the time of the last quantifiable concentration.
| hour | Group B Mild Hepatic Impairment |
|---|---|
| Plasma Lorlatinib Metabolite Tlast at Steady State | NA (NA to NA) |
MRAUC24 was defined as metabolite ratio of lorlatinib metabolite for AUC24.
| Ratio | Group B Mild Hepatic Impairment |
|---|---|
| Metabolite Ratio of Lorlatinib Metabolite for AUC24 (MRAUC24) at Steady State on Cycle 2 Day 1 | NA ± NA |
MRAUClast was defined as metabolite ratio of lorlatinib metabolite for AUClast.
| Ratio | Group B Mild Hepatic Impairment |
|---|---|
| Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 2 Day 1 | NA ± NA |
MRCmax was defined as metabolite ratio of lorlatinib metabolite for AUClast.
| Ratio | Group B Mild Hepatic Impairment |
|---|---|
| Metabolite Ratio of Lorlatinib Metabolite for Cmax (MRCmax) at Steady State on Cycle 2 Day 1 | NA ± NA |
MRAUClast was defined as metabolite ratio of lorlatinib metabolite for AUClast.
| Ratio | Group B Mild Hepatic Impairment |
|---|---|
| Metabolite Ratio of Lorlatinib Metabolite for AUClast (MRAUClast) at Steady State on Cycle 1 Day 1 | NA ± NA |
Collected over From Screening (within 28 days prior to Cycle 1 Day 1) through and including at least 28 days after after the last lorlatinib dose. The duration is approximately 42 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group B Mild Hepatic Impairment | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Event | Group B Mild Hepatic Impairment |
|---|---|
| Nervous system disordersNervous system disorders | 1/1 |
| Psychiatric disordersPsychiatric disorders | 1/1 |
| Event | Group B Mild Hepatic Impairment |
|---|---|
| General disordersGeneral disorders | 1/1 |
| Metabolism and nutrition disordersMetabolism and nutrition disorders | 1/1 |
| Nervous system disordersNervous system disorders | 1/1 |
| Psychiatric disordersPsychiatric disorders | 1/1 |
| Age, Categorical(Participants) | Group B Mild Hepatic Impairment |
|---|---|
| <=18 years | NA |
| Between 18 and 65 years | NA |
| >=65 years | NA |
| Sex: Female, Male(Participants) | Group B Mild Hepatic Impairment |
|---|---|
| Female | NA |
| Male | NA |
| Ethnicity (NIH/OMB)(Participants) | Group B Mild Hepatic Impairment |
|---|---|
| Hispanic or Latino | NA |
| Not Hispanic or Latino | NA |
| Unknown or Not Reported | NA |
| Race (NIH/OMB)(Participants) | Group B Mild Hepatic Impairment |
|---|---|
| American Indian or Alaska Native | NA |
| Asian | NA |
| Native Hawaiian or Other Pacific Islander | NA |
| Black or African American | NA |
| White | NA |
| More than one race | NA |
| Unknown or Not Reported | NA |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jan 2020 to primary completion in Jul 2021, 17 months.
Results were first posted in Jun 2024, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorlatinib